Search tips
Search criteria 


Logo of frontoncoLink to Publisher's site
Front Oncol. 2013; 3: 196.
Published online 2013 July 30. doi:  10.3389/fonc.2013.00196
PMCID: PMC3727077

Compartment Model Predicts VEGF Secretion and Investigates the Effects of VEGF Trap in Tumor-Bearing Mice


Angiogenesis, the formation of new blood vessels from existing vasculature, is important in tumor growth and metastasis. A key regulator of angiogenesis is vascular endothelial growth factor (VEGF), which has been targeted in numerous anti-angiogenic therapies aimed at inhibiting tumor angiogenesis. Systems biology approaches, including computational modeling, are useful for understanding this complex biological process and can aid in the development of novel and effective therapeutics that target the VEGF family of proteins and receptors. We have developed a computational model of VEGF transport and kinetics in the tumor-bearing mouse, which includes three-compartments: normal tissue, blood, and tumor. The model simulates human tumor xenografts and includes human (VEGF121 and VEGF165) and mouse (VEGF120 and VEGF164) isoforms. The model incorporates molecular interactions between these VEGF isoforms and receptors (VEGFR1 and VEGFR2), as well as co-receptors (NRP1 and NRP2). We also include important soluble factors: soluble VEGFR1 (sFlt-1) and α-2-macroglobulin. The model accounts for transport via macromolecular transendothelial permeability, lymphatic flow, and plasma clearance. We have fit the model to available in vivo experimental data on the plasma concentration of free VEGF Trap and VEGF Trap bound to mouse and human VEGF in order to estimate the rates at which parenchymal cells (myocytes and tumor cells) and endothelial cells secrete VEGF. Interestingly, the predicted tumor VEGF secretion rates are significantly lower (0.007–0.023 molecules/cell/s, depending on the tumor microenvironment) than most reported in vitro measurements (0.03–2.65 molecules/cell/s). The optimized model is used to investigate the interstitial and plasma VEGF concentrations and the effect of the VEGF-neutralizing agent, VEGF Trap (aflibercept). This work complements experimental studies performed in mice and provides a framework with which to examine the effects of anti-VEGF agents, aiding in the optimization of such anti-angiogenic therapeutics as well as analysis of clinical data. The model predictions also have implications for biomarker discovery with anti-angiogenic therapies.

Keywords: systems biology, mathematical model, computational model, angiogenesis, tumor xenograft model, anti-angiogenic therapy, cancer


Angiogenesis is the formation of new blood capillaries from pre-existing vessels, and is a process involved in physiological function, such as exercise and wound healing, as well as disease conditions, including cancer, peripheral and coronary artery diseases, pre-eclampsia, and age-related macular degeneration (AMD). The vascular endothelial growth factor (VEGF) family is a key promoter of angiogenesis and vascular development. The VEGF family includes five ligands: VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placental growth factor (PlGF). One of the most widely studied members is VEGF-A, commonly referred to as VEGF. Alternative splicing of VEGF produces different isoforms, including VEGF121, VEGF165, VEGF189, and VEGF206 in humans. Expressed rodent isoforms are one amino acid shorter than human isoforms; therefore, the subscripted number is one less. Additionally, there are VEGFxxxb isoforms, which have been shown to be endogenous anti-angiogenic species (1, 2). VEGF promotes angiogenesis by binding to and activating its receptors VEGFR1 and VEGFR2, and co-receptors called neuropilins (NRPs). Signal transduction through the receptors promotes many cellular processes, including cell proliferation, migration, and survival (3). VEGFR1 and VEGFR2 are expressed on endothelial cells (ECs), cancer cells, and other cell types, including bone marrow-derived cells and neurons [see (4) for review]. NRPs are expressed on various cell types, including ECs, tumor cells, and muscle fibers (4).

Angiogenesis has been targeted to treat diseases characterized by reduced vascularization (“pro-angiogenic therapy”) (5, 6) or to inhibit the formation of new blood vessels in conditions leading to hypervascularization (“anti-angiogenic therapy”) (7, 8). Of particular importance is anti-angiogenic therapy targeting tumor vascularization. Bevacizumab (9) is a recombinant monoclonal antibody that neutralizes VEGF and is approved by the Food and Drug Administration to treat colorectal cancer, glioblastoma, kidney cancer, and non-small cell lung cancer. Aflibercept (Regeneron) is a soluble decoy receptor approved to treat metastatic colorectal cancer and wet AMD. The drug is also in clinical trials to evaluate its anti-angiogenic effect on various forms of cancers (10). Aflibercept binds to VEGF more tightly than bevacizumab (11) and forms a 1:1 complex with VEGF and PlGF (12). In addition to therapies that target the VEGF ligand, several tyrosine kinase inhibitors (TKIs) have been developed to target phosphorylation of VEGF receptors, as well as other pro-angiogenic receptors including platelet-derived growth factor (PDGF) receptors and fibroblast growth factor (FGF) receptors (13, 14).

Systems biology approaches, including quantitative experimental methods and mathematical modeling, have been applied to study angiogenesis (15,17). Computational models complement experimental studies and can aid in the development and optimization of effective therapeutics (18). Despite extensive basic science and translational research to develop anti-angiogenic therapies, little is known about the drugs’ mechanism of action, how and why tumors become resistant to the treatment, or the patient population that can benefit most from these drugs. Identifying biomarkers that can be used to predict the patients whose tumors will respond favorably to anti-angiogenic treatment is of great interest (19,21). Computational approaches can shed light upon these issues by providing a framework to generate and test hypotheses related to VEGF kinetics and transport in the body (14, 22).

We have previously developed an experiment-based compartment model of VEGF distribution in non-tumor-bearing mice, which estimates the distribution of VEGF in the body (23). Additionally, the model was used to fit kinetic parameters and to predict the rate at which VEGF is secreted by muscle fibers, which is difficult to measure experimentally in vivo. In this work, we present an expanded model that includes a tumor compartment and incorporates several new features: EC secretion of VEGF, soluble factors that influence VEGF levels, and a dynamic tumor volume. These new elements lead to a more physiological model and incorporate experimental observations relevant to VEGF kinetics and transport in the whole body, which can be compared to experimental data. Thus, this work represents a significant expansion to our previous models (23,26). We first re-calibrate the two-compartment model (no tumor is present) using in vivo experimental data and estimate the rates at which VEGF is secreted by muscle fibers and ECs, as well as the clearance rates of unbound and complexed VEGF Trap, and the binding affinity of VEGF trap. We then fit the three-compartment model to available in vivo experimental data in order to estimate the rate of VEGF secretion by muscle fibers, ECs, and tumor cells. We demonstrate how the model can be applied to investigate the effect of neutralizing VEGF using VEGF Trap. These results contribute to our understanding of the efficacy of VEGF Trap in specific tumor types. We also estimate the concentrations of VEGF in different compartments, which can be validated experimentally.


Re-calibration of two-compartment model captures dynamics of bound and complexed VEGF Trap

The previous two-compartment model simulating non-tumor-bearing mice (23) did not include EC secretion of VEGF or soluble factors. Therefore, we first refit the expanded two-compartment model that includes these additional features in order to match in vivo experimental data (12). The fitting optimized the values of five parameters: VEGF secretion rate of muscle fibers (qVEGFmuscle), VEGF secretion rate of ECs (qVEGFEC), clearance rate of VEGF Trap (cA), clearance rate of the VEGF/VEGF Trap complex (cVA), and dissociation constant of VEGF and VEGF Trap (Kd). As described in the methods, although the experimental protocol used by Rudge and coworkers utilizes subcutaneous administration of VEGF Trap, we simulate intravenous administration and assume 100% of the reported dose is administered. The fitting procedure allows us to estimate the values of the free parameters using in vivo experimental data.

The optimized parameter values are shown in Table Table1,1, and all raw data from the optimization is given in File 1 in Supplementary Material. The optimized value of Kd is comparable to the reported in vitro measurement of 0.6 pM (11), providing confidence in the fitting procedure. The optimization predicts the muscle fibers secrete very little VEGF (0.002 molecules/cell/s), and the standard deviation of the optimized values is high. This suggests that the model is not sensitive to the value of (qVEGFmuscle). To investigate this possibility, we varied muscle secretion from 0 to 0.02 molecules/cell/s and used the model to estimate the concentrations of unbound VEGF Trap and the mouse VEGF (mVEGF)/VEGF Trap complex. This sensitivity study revealed that increasing (qVEGFmuscle) up to one order of magnitude does not significantly change the fit, as shown in Figure Figure1.1. These results indicate that there may not be sufficient data to determine VEGF secretion from muscle fibers. Specifically, it is difficult to separate the contribution of VEGF from muscle fibers, compared to ECs. This result is not specific to the data used here, but more generally that plasma measurements cannot be used to determine endogenous VEGF production from multiple sources.

Table 1
Estimated model parameters from optimization of two-compartment model.
Figure 1
Effect of varying muscle secretion in two-compartment model. The estimated plasma levels of free VEGF Trap (dashed lines) and mouse VEGF bound to VEGF Trap (solid lines) after a single intravenous injection of VEGF Trap at (A), 0.5 mg/kg; (B) ...

Sensitivity analysis reveals model parameters that influence VEGF concentrations

In the three-compartment model, the values of several parameters are based on characterization of the human VEGF (hVEGF) system due to a lack of quantitative experimental measurements in mice. We previously investigated sensitivity to individual parameters, including vascular permeability, lymphatic drainage, and properties of the anti-VEGF agent (25). In that work, parameters were varied one by one. Here, we perform a modular sensitivity analysis, where we investigate how variability in three sets of parameters (model inputs) influence mouse and hVEGF concentrations and sVEGFR1 levels in normal tissue, blood, and tumor (model outputs). Specifically, we investigated the effect of VEGF receptor expression, transport parameters, and kinetic parameters using the extended Fourier Amplitude Sensitivity Test (eFAST), as described in the Section “Materials and Methods.” Two indices provide an estimate of the sensitivity of the model output to model parameters. The first FAST index quantifies the variance of a model output with respect to the variance of each input. The total FAST index quantifies the variance of a model output with respect to the variances of each input and covariances between all combinations of inputs. If total FAST indices are larger than the first FAST indices, it means that the parameter is more important in combination with other parameters rather than individually.

The FAST indices for each set of model inputs are shown in Figure Figure2.2. When investigating the effect of tumor cell receptor expression, VEGF and sVEGFR1 concentrations are sensitive to the density of NRP co-receptors. Additionally, the level of VEGFR1 is an important determinant of hVEGF concentration in the tumor. In the transport module, the rate of lymphatic flow from normal or tumor tissue in concert with other transport parameters is estimated to influence hVEGF levels in plasma and normal tissue. Soluble VEGFR1 concentrations, as well as mVEGF levels in plasma and normal tissue, are particularly sensitive to the permeability of the normal tissue to VEGF and VEGF/sVEGFR1 complexes. Individual parameters investigated in the kinetic module are predicted to influence VEGF and sVEGFR1 concentrations, rather than in combination with other kinetic parameters. VEGF and sVEGFR1 levels are particularly sensitive to VEGF164 and VEGF165 binding to NRP co-receptors and VEGF binding to VEGFR1. These results aid in our understanding of how uncertainty in the values of particular parameters influence the model output. Additionally, the sensitivity analysis provides quantitative data to support obtaining additional experimental measurements of specific parameters that significantly influence model outputs.

Figure 2
Sensitivity indices of model parameters. The extended Fourier Amplitude Sensitivity Test (eFAST) was used to estimate the variance in the model output with respect with variance in individual model inputs (first FAST indices) and covariances in combinations ...

The rate of VEGF secretion by human tumor cells is dependent on the tumor microenvironment

Tumor cells are a source of VEGF; however, there is a lack of in vivo data for VEGF secretion rates. Therefore, we have used in vivo experimental data on the plasma concentration of free VEGF Trap and VEGF Trap bound to mouse and hVEGF to determine VEGF secretion rates in mice bearing human tumor xenografts. Here, we use the clearance rates of unbound and complexed VEGF Trap predicted in the two-compartment model and experimentally determined VEGF binding affinity. However, the VEGF secretion rates (qVEGFmuscle, qVEGFEC, and tumor VEGF secretion, qVEGFtumor) were optimized to fit experimental data. We optimize the VEGF secretion rates since there is large variability in the predicted rate of muscle secretion obtained using the two-compartment model.

The VEGF secretion rates were predicted using the optimization algorithm, assuming the tumors follow either the average (baseline) or fast tumor growth profiles. We use data from Rudge et al. (12), where tumors were allowed to grow to ~100 mm3, and then the tumor-bearing mice were injected with VEGF Trap (“anti-VEGF”) twice weekly for 2 weeks. Various dosages of VEGF Trap were used, and the concentrations of free VEGF Trap and the mVEGF/VEGF Trap complex and hVEGF/VEGF Trap complex in the blood were measured. These measurements can be directly compared to model estimates where the anti-VEGF agent is administered intravenously. The optimized model provides a good fit to the experimental data, as shown in Figure Figure3.3. The average and standard deviation of the predicted VEGF secretion rates from the optimization runs are in Figure Figure44 and Table Table2,2, and File 1 in Supplementary Material contains the raw data.

Figure 3
Predicted systemic VEGF Trap levels. The model predicts the plasma levels of free VEGF Trap (black lines), mouse VEGF bound to VEGF Trap (blue lines), and human VEGF bound to VEGF Trap (red lines). VEGF Trap was administered twice per week for 2 weeks ...
Figure 4
Optimized VEGF secretion rates. The model parameters were optimized to fit experimental data, and the values of normal, EC, and tumor VEGF secretion rates were determined. The mean optimal secretion rates and standard deviation of 20 optimization runs ...
Table 2
Estimated VEGF secretion rates from optimization of three-compartment model.

Circulating levels of VEGF Trap and human VEGF/VEGF Trap complex and maximum concentration of total VEGF Trap vary with dose

To our knowledge, the dynamic levels of free and complexed VEGF Trap in tumor-bearing mice have not been reported. These data are useful in elucidating the mechanism of action of VEGF Trap and to determine if the dosage is sufficient to neutralize VEGF secreted by the tumor. Therefore, we used the optimized model for A673 rhabdomyosarcoma human xenograft to predict the concentration profiles for free VEGF Trap and VEGF Trap bound to hVEGF (Figure (Figure5).5). The level of VEGF Trap bound to hVEGF is more than an order of magnitude lower than the concentration of mVEGF complexed with VEGF Trap. This result is consistent with the finding that normal production of VEGF eclipses the production from tumors, as described by Rudge and co-authors (12). Additionally, the level of free VEGF Trap remains well above the level of the hVEGF/VEGF trap complex for up to 14 days. This indicates effective dosing, as the VEGF-neutralizing agent is able to neutralize all VEGF secreted by the tumor. The HT1080 fibrosarcoma tumor response is similar (data not shown).

Figure 5
Predicted concentration profiles of systemic VEGF Trap. The optimized model was applied to predict the time course of free VEGF Trap (black), mouse VEGF bound to VEGF Trap (blue), and human VEGF bound to VEGF Trap (red) in the mouse plasma after a single ...

VEGF Trap is predicted to deplete unbound VEGF in the body

The optimized model of a tumor-bearing mouse provides a framework with which to study the concentration of unbound VEGF before and after administration of VEGF Trap. As expected, endogenous levels of unbound VEGF are highest in the normal tissue and plasma, and the concentration of hVEGF is highest in the tumor, based on the source of mouse and hVEGF. Before any injection, mVEGF concentration is estimated to range from 0.17 to 1.47 pM in mice with A673 tumors, based on 1 SD above and below the average predicted VEGF secretion rates (Table (Table3).3). Unbound hVEGF in the tumor is estimated to be ~0.5 pM. We also present free VEGF concentration during twice-weekly injections of VEGF Trap at 2.5 mg/kg (Figures (Figures6A,B).6A,B). The model estimates that free VEGF in the body is first depleted before increasing slightly before the next injection. Thus, the model can be used to understand the effect of anti-VEGF agents on systemic and tissue levels of VEGF.

Table 3
Estimated concentrations of free VEGF before VEGF Trap injection.
Figure 6
Predicted concentration profiles of unbound VEGF. The optimized model was applied to predict the time course of free VEGF and the fraction of free VEGF in the form of VEGF164 or VEGF165 in normal tissue (blue), plasma (red), and tumor (black) twice-weekly ...

In addition to using the model to estimate the concentration of unbound VEGF, we have also determined the percentage of free VEGF in the form of VEGF164 or VEGF165. The isoform secretion ratio for VEGF164:VEGF120 in muscle is 92:8 and 90:10 in EC, and the secretion ratio for VEGF165:VEGF121 in tumor cells is 50:50, as described in the Section “Materials and Methods.” These ratios determine the fraction of VEGF164 or VEGF165 in the compartments; and, the fractions at which the isoforms are present change with time and drug dose. Here, we consider a dosage of 2.5 mg/kg. After the first anti-VEGF injection, the percentage of free mVEGF in the form of VEGF164 is ~90% in all compartments (Figure (Figure6C,6C, left). The percentage of hVEGF in the form of VEGF165 in tumor is slightly lower than the percentage of VEGF165 in normal tissue and plasma (44–49%, as compared to 55%; Figure Figure6D).6D). These types of model predictions can aid in biomarker identification, as the concentration of specific VEGF isoforms may predict tumors that will respond to anti-VEGF treatment or other anti-angiogenic therapies.

We also apply the model to investigate the total levels of circulating VEGF in plasma. The soluble factors sVEGFR1 and α-2-macroglobulin (α2M) bind to VEGF and contribute to circulating levels of VEGF. Thus, total circulating VEGF is comprised of free VEGF, VEGF bound to sVEGFR1, and α2M-bound VEGF (both the native and active forms). VEGF bound to the VEGF Trap drug is also included. We again allow the tumors to reach a volume of 100 mm3 before simulating twice-weekly injections of VEGF Trap at varying doses. Before the first injection, the relative amounts of free, sVEGFR1-bound, and α2M-bound circulating VEGF are 80, 4, and 16%, respectively. One day after the first injection of VEGF Trap, the composition of the circulating VEGF changes, depending on the drug dose (data not shown). If we consider a drug dose of 2.5 mg/kg, the relative amounts of free, sVEGFR1-bound, α2M-bound, and VEGF Trap-bound VEGF are 0.6, 0.03, 5, and 94%, respectively. Thus, the VEGF Trap displaces the soluble factors bound to VEGF.


We have developed a compartment model of VEGF distribution in tumor-bearing mouse. The model incorporates tumor-specific properties, including the rate of tumor growth and VEGF secretion. We have used in vivo experimental data for the levels of free and bound VEGF Trap in mice bearing human tumor xenografts in order to predict the endogenous rate of VEGF secretion by myocytes and ECs and compared them to the predicted secretion rates in normal mice. We also predicted the rate at which cells from different human tumor xenografts secrete VEGF. To our knowledge, VEGF secretion rates can only be obtained from in vitro experiments and cannot be directly measured in vivo; however, VEGF concentrations that depend on the secretion rates can be measured experimentally, although such interstitial measurements are presently not available. Therefore, this work provides new insight into VEGF levels in a pre-clinical in vivo model of cancer. In addition, using the optimized model for tumor-bearing mice, we have estimated the concentration of VEGF in the mouse following administration of VEGF Trap, as well as the distribution of VEGF in mice and circulating levels of VEGF Trap and the VEGF/VEGF Trap complex. These results show that the concentration of free VEGF in the tumor depends on the tumor-specific properties such as the rate of tumor growth and the amount of VEGF secreted by tumor cells. Lastly, we used the predicted level of VEGF Trap and hVEGF/VEGF Trap complex to compare various dosages. The model predicted that all hVEGF originating from the tumor is neutralized at higher doses of the drug. This demonstrates an important application of the model: to incorporate tumor-specific properties and investigate the efficacy of different drug doses.

We used the two-compartment model to estimate VEGF secretion rates, clearance of free and bound VEGF Trap, and the binding affinity of VEGF Trap for normal mice. The value of binding affinity of VEGF Trap estimated by the model is comparable to the experimentally measured value (11). Additionally, the estimated EC secretion is comparable to the experimentally determined value of 0.028 molecules/cell/s (27). However, the predicted rate at which muscle cells secrete VEGF is very low, and varying this parameter over one order of magnitude does not significantly change the fit. In contrast, EC secretion can be specified and changing this parameter drastically influences the fit to experimental data (results not shown). These results may indicate that the rate of VEGF secretion from muscle and ECs cannot be simultaneously estimated using the available experimental data. That is, measurements of free and bound VEGF Trap in plasma do not allow us to distinguish how muscle and ECs contribute to VEGF levels. Additional experimental measurements such as interstitial levels of VEGF in skeletal muscle are needed in order to predict VEGF secretion by muscle fibers with confidence. Currently, interstitial VEGF concentrations are only available in human tissue (28,33); however, similar studies in mice are of great interest.

We found that fitted parameters from normal mice were not sufficient to match the levels of unbound and complexed VEGF Trap in the model of tumor-bearing mice. We first attempted to use the fitted parameters from the two-compartment model in the model of tumor-bearing mice and use in vivo experimental data to fit the rate of VEGF secretion from tumor cells. However, the model overestimated the amount of VEGF Trap complexed with mVEGF (results not shown). We are able to more closely fit the experimental data for the tumor-bearing mice by optimizing the three-compartment model independent of the optimized model for normal mice. This indicates that endogenous VEGF secretion may be different in normal and tumor-bearing mice (Tables (Tables11 vs vs2).2). Experimental studies are needed to validate these results; however, evidence shows that VEGF secretion is reduced following administration of VEGF Trap (34) or other anti-angiogenic therapies (35,37).

The three-compartment model predicted that the in vivo tumor VEGF secretion rates needed to fit experimental data are lower than data obtained from in vitro measurements. In vitro experimental measurements of the VEGF secretion rate vary widely: 0.03–2.65 molecules/cell/s (3841). We predicted that human tumors secrete VEGF at rates range ranging from 0.007 to 0.023 molecules/cell/s. Interestingly, there is little variability in the predicted tumor secretion rate, as indicated by the small standard deviation (~10−5 molecules/cell/s). Having experimental measurements of the plasma concentration of VEGF Trap bound to hVEGF (i.e., VEGF originating from the tumor) enables us to predict the rate at which the tumor secretes VEGF in vivo. In this way, xenograft models are preferable to syngeneic tumor models, in which VEGF derived from tumor and other tissues are indistinguishable. Similarly, plasma measurements in human patients would not be sufficient to specify tumor VEGF. Thus, xenograft models provide unique insight into the effects of anti-angiogenic therapies and are relevant to human studies.

Tumor VEGF secretion is predicted to depend on the tumor microenvironment. HT1080 tumors are predicted to secrete ~2-fold more VEGF than A673 tumors. Additionally, average- and fast-growing tumors are predicted to secrete different amounts of VEGF, where VEGF secretion in fast-growing tumors is slightly lower than that of tumors that grow at an average rate. To our knowledge, experimental data for VEGF secretion rates is limited to in vitro measurements. Therefore, the ability to use the model to determine the VEGF secretion from in vivo data and track and quantify normal and tumor VEGF are important features of the model.

Using the optimized model, it is possible to estimate VEGF concentrations in the mouse before and after VEGF Trap administration. In the model, we allowed the tumor to grow for 2 weeks before the VEGF Trap injection. Just before the injection, the estimated plasma VEGF levels are within the range of experimental measurements in mouse of 0.3–1.4 pM (42, 43). The model indicates that plasma VEGF depends on properties of the tumor, such as volume, a result that is validated by experimental evidence (44). Using the model, free VEGF in muscle interstitium is predicted to range from 0.2 to 1.5 pM. To our knowledge, interstitial VEGF in normal tissues has only been quantified in human samples. Interstitial muscle VEGF in humans ranges from 0.3 to 3 pM (2833, 45). It is not clear how this concentration range varies across species. However, since the range of plasma VEGF measurements is similar between mice and humans, where human plasma VEGF is measured to be 0.4–3 pM (46), it is possible that interstitial VEGF is also comparable in mice and humans. Thus, our model results and predictions provide a framework to compare VEGF distribution in different species and can be experimentally validated. Additionally, we are able to predict the concentration of specific VEGF isoforms (i.e., the percentage of free VEGF in the form of VEGF164 or VEGF165, as compared to the shorter isoforms VEGF120 or VEGF121). These results may be useful in identifying predictive biomarkers for anti-VEGF treatment, where the level of VEGF121 is being evaluated as a biomarker (47, 48). We also applied the model to estimate the relative contribution of sVEGFR1-bound and α2M-bound VEGF to total circulating VEGF. The soluble factors compete with anti-VEGF agents; therefore, it is of interest to investigate the effect of sVEGFR1 on the response to anti-VEGF treatment. In this way, the model complements studies evaluating sVEGFR1 as a potential biomarker to predict resistance to anti-VEGF treatment (49).

We can also compare the estimated levels of plasma VEGF generated by the model following administration of VEGF Trap with experimental studies. In vivo studies of mice with breast tumor xenografts indicate the plasma VEGF is reduced following VEGF Trap treatment, particularly at the higher doses (34). Additionally, Hoff and coworkers report that VEGF Trap is able to bind all free VEGF 11 days after treatment in an experimental model of rat glioma (50). These studies support the computational model predictions. However, we are not aware of animal studies that provide the time course of VEGF and VEGF/VEGF Trap concentration, which is an important contribution of the model and can complement pre-clinical studies that investigate the efficacy of VEGF Trap.

We show that interstitial tumor VEGF levels depend on specific properties of the tumor. To our knowledge, there are no experimental measurements for interstitial tumor VEGF concentrations. However, a sampling of available experimental measurements of total VEGF in tumor tissue (free and bound VEGF, both intracellular and extracellular) reveals a wide range of values, depending on tumor type and size. File 1 in Supplementary Material shows a compilation of measurements of tumor VEGF for various tumor types. Experimental studies to measure free VEGF in tumor tissue in mouse models would provide much needed quantitative data to test and validate the model predictions presented here.

Model limitations

We consider the model presented here to be a minimal model that accurately reproduces experimental data, both qualitatively and quantitatively. The model includes several assumptions, which may be addressed as quantitative data become available. For example, we assume the normal tissue is skeletal muscle, although other tissues and organs secrete and contain VEGF (51), but are not as well-characterized as muscle. We include two major VEGF isoforms (VEGF120/VEGF121 and VEGF164/VEGF165); however, other isoforms such as VEGF188/VEGF189 (52) and VEGFxxxb (53, 54) also influence angiogenesis and may impact anti-VEGF therapies. Recent studies also show that other VEGF ligands and receptors contribute to angiogenesis (55,57), and the model can be expanded in the future to include these molecular species. Additionally, although platelets contain large amounts of VEGF and contribute to angiogenesis (58), we have not included them in the model as the rate and conditions under which they secrete or unload VEGF are unknown. We assume that as the tumor grows, the relative proportions of interstitial space, vascular volume, and tumor cells remain constant. However, experimental studies indicate that these proportions should change as the tumor grows (59). Finally, we have not included the effects of anti-VEGF treatment on tumor volume or vascular permeability. Pre-clinical studies show tumor growth inhibition and even regression of the tumor following anti-angiogenic therapy that targets VEGF. We have performed preliminary studies where the tumor volume is constant after 1 week of anti-VEGF treatment since experimental studies indicate that tumor growth is halted during 2 weeks of twice-weekly VEGF Trap injections (34). We found that the predicted tumor secretion rate is slightly larger when accounting for tumor growth stagnation. This is because the tumor is smaller and consists of fewer cells. Therefore, the amount of VEGF that must be secreted on a per cell basis in order to obtain a certain level of VEGF or VEGF/VEGF Trap complex is higher. Tumor permeability may decrease with anti-angiogenic therapy, as the tumor normalizes neovasculature and it begins to resemble normal vessels; however, we have not included that effect in the current model. In a human model of VEGF transport and kinetics, we considered “low” and “high” vascular permeability between the tumor and blood (22). Interestingly, the model predicts that tumor VEGF can increase above the pre-treatment level depending on properties of the tumor microenvironment, even when tumor permeability is high. Future computational studies may investigate the effect of anti-VEGF treatment on tumor volume and vascular permeability in greater detail.


The compartment model presented here provides a framework to investigate the action of VEGF-targeting agents for particular types of tumors. The physiologically based and experimentally validated model, based on currently available animal data, predicted the dynamic concentrations of molecular species and other biological parameters that are difficult to quantify experimentally. Thus, the model complements pre-clinical experiments, can aid in the development of agents that target VEGF and inhibit angiogenesis, and may be useful in evaluating biomarkers of anti-angiogenic therapies. The model can be extended to human patients; this is particularly important since in 2012 aflibercept has been approved to treat metastatic colorectal cancer in humans (60).

Materials and Methods

Computational model

We have expanded the two-compartment model of VEGF distribution in the mouse (23) to include tumor tissue (“tumor compartment”). The model is illustrated in Figure Figure7.7. Geometric and kinetic parameters for the normal and blood compartments have been fully detailed in (23). By simulating a human tumor xenograft (tissue that grows from human cancer cells that have been injected into the mouse), we also incorporate hVEGF isoforms and cross-species reactions between ligands and receptors. Specifically, we include VEGF121 and VEGF165, which are secreted by tumor cells. The human isoforms can bind to human receptors present on tumor cells, as well as mouse receptors on endothelial surfaces in the body (normal and tumor EC) and muscle fibers in the normal compartment. Additionally, the mouse isoforms bind to mouse receptors on muscle fibers and ECs and human receptors on tumor cells. The model can also be adapted to simulate mouse syngeneic tumors, where the tumor cells secrete VEGF120 and VEGF164; in this case, only mVEGF is present in the model. In this work, however, we have focused on human tumors. The molecular interactions between VEGF and its receptors are illustrated in Figure Figure88.

Figure 7
Three-compartment model of VEGF. The model is comprised of three-compartments: normal tissue, blood, and tumor. VEGF120 and VEGF164 are secreted by myocytes in the normal tissue and by EC in all compartments. Tumor cells secrete the human isoforms VEGF ...
Figure 8
Molecular interactions. The interactions of VEGF120 and VEGF164 are illustrated. VEGF121 is involved in the same binding reactions as VEGF120. Similarly, the interactions for VEGF165 are the same as VEGF164. Differences in the interactions of VEGF120/121 ...

In addition to introducing the tumor compartment, we include VEGF interactions with two soluble factors: soluble VEGFR1 (sVEGFR1) and α2M and introduce VEGF secretion by ECs. Soluble VEGFR1 is secreted by ECs and transported throughout the body, enabling it to interact with VEGF in all compartments. The soluble factor α2M is present in two forms: native and active (α2Mfast) (61). Both forms are present at high concentrations (nanomolar to micromolar levels) (62), and due to their size (720 kDa MW), we assume that both forms are confined to the blood compartment. The model predicts the levels of free VEGF in the tissue interstitium and in plasma. These soluble factors interfere with assays that measure VEGF concentration, making it difficult to distinguish between VEGF that is truly free versus VEGF that is bound to trapping molecules (63). Both sVEGFR1 and α2M can sequester VEGF and reduce the levels of free VEGF. Therefore, it is important to include these factors in the model.

We have also included VEGF secretion by ECs, as experimental studies demonstrate that EC are a source of VEGF (64, 65). The luminal and abluminal endothelial surfaces secrete VEGF, and luminal secretion is predicted to be a major determinant of plasma VEGF. Due to EC secretion of VEGF, the compartments are relatively autonomous, since the concentration of VEGF in each compartment is determined primarily by the secretion rate in that compartment, as well as the microenvironmental variables of the compartment; however, transport between compartments is also important.

The model is described by 258 non-linear ordinary differential equations (ODEs), including 53 for the normal compartments, 126 for the blood, and 79 for the tumor compartment. In addition to the ODEs that describe how the species’ concentrations vary with time, we include an equation for the tumor volume, such that the model simulates VEGF distribution in tumor-bearing mice, immediately following inoculation of tumor cells. The initial tumor volume is 10−6 cm3. A sampling of experimental data for the volume of xenografts generated from MCF-7 and MDA-MB-231 breast cancer cells (66,74) reveals various growth profiles. We fit the data to exponential curves, accounting for a range of tumor growth profiles (Figure (Figure9).9). The growth curves fit experimental data well, within the time scales used in the model (i.e., <6 weeks). In cases where the model is run for longer times, different growth curves should be used in order to capture the full range of tumor growth dynamics for the desired time scale. The complete set of equations, chemical reactions, and glossary of terms are given in File 2 in Supplementary Material.

Figure 9
Tumor growth profiles. We investigate the growth profiles of two categories of tumors: average- (blue) and fast-growing (green) tumors, based on available experimental data. The data are fit to exponential curves, and the growth equations are given in ...

Simulation of administration of VEGF Trap

Experimental studies utilize a subcutaneous injection of VEGF Trap (“anti-VEGF”); however, the authors of the experimental study state that the bioavailability of the drug is the same whether injected subcutaneously or intravenously (12). The current model does not include a subcutaneous compartment; therefore, we simulate an intravenous injection, which inherently assumes that all of the drug appears in the blood. Injection lasts for 1 min (the duration does not affect the results, within limits) and is performed once the tumor reaches a particular volume, according to experimental methods described by Rudge et al. (12). Various doses of VEGF Trap are used, as reported by Rudge and coworkers (12) (0.5, 1, 2.5, 10, and 25 mg/kg).

Sensitivity analysis

In order to understand the impact of various parameters, we perform variance-based global sensitivity analyses using the eFAST (75). The eFAST method estimates the sensitivity of model outputs (i.e., VEGF concentration) with respect to variations in model parameters. The three-compartment model is run multiple times with different parameter sets, where all parameters are varied from their baseline values. Variance for a parameter i is:


where Aj and Bj are the Fourier coefficients of the cosine series and sine series, respectively, for the frequency, j, associated with the parameter i and include harmonics, p, of the base frequency. The total variance in the output is:


The variances are used to estimate two indices that provide a measure the sensitivity: first-order FAST indices, Si, and the total FAST indices, STi. The first-order indices measure the local sensitivity and do not account for interactions with other parameters:


The Total FAST indices measure of global sensitivity and take into account second- and higher-order interactions between parameters. STi are calculated by excluding the effects of the complementary set of other parameters:


The eFAST method has been applied to systems biology models (76), and our laboratory has previous used the method to investigate the sensitivity of VEGFR2 signaling (77). In this work, we apply eFAST to investigate the sensitivity of steady state VEGF concentrations with respect to kinetic parameters, transport parameters, and receptor expression levels. We use Simlab 2.2 from Econometrics and Applied Statistics Unit EAS at the Joint Research Centre of the European Commission to implement eFAST.

Numerical implementation

The model equations were implemented in MATLAB using the SimBiology toolbox and were solved with the Sundials solver. The model is available in SBML format at:



The geometric parameters for the tumor compartment are summarized in Table A1 in Appendix. The tumor cells are assumed to have the same volume as the MCF-7 breast tumor cells, which have a mean diameter of 12 μm (78). A sphere of this diameter would have a volume and surface area of 905 μm3 and 452 μm2, respectively. However, since tumor cells are not spherical, we assume a dodecahedral cell of the same volume, which has a surface area of 497 μm3. The average luminal diameter of capillaries in growing MCF-7 xenografts is 13.94 μm (79), and imaging of tumor vasculature supports this value (80). We assume an EC thickness of 0.5 μm, which would yield a cylindrical cross-sectional area of 175 μm2 and an outer perimeter of 46.9 μm. However, microvessels are not cylindrical. Therefore, to find the true perimeter, we used a relationship between total perimeter and total cross-sectional area in breast cancer capillaries, where the increase in perimeter is 23% (81, 82), yielding a capillary perimeter of 57.7 μm.

The extracellular fluid volume fraction in the breast tumor xenografts has been shown to range from 33 to 76% (78). Another measurement reports the extracellular fluid volume in MCF-7 tumors to be 40% (83). We assume a value of 45%, which is divided into interstitial space and intravascular space. We set the volume fraction of intravascular space to be 10%, which is within the range of available experimental data (84,86). Given the capillary dimensions described above and an intravascular volume of 10%, the capillary density is calculated to be 655 capillaries/mm2. Based on a cell thickness of 0.5 μm, the volume occupied by the ECs of the microvessels is 1.5%. Cancer cells occupy the remaining tissue volume of 53.5%. The volume fractions of microvessels and tumor cells are then used to calculate the total surface area of all vessels and tumor cells per unit volume of tissue: 378 cm2 EC surface/cm3 tissue and 2939 cm2 tumor cell surface/cm3 tissue.

The interstitial space is composed of extracellular matrix (ECM), and basement membranes associated with the microvessels (endothelial basement membrane, EBM) and tumor cells (parenchymal basement membrane, PBM). The thickness of the basement membranes is assumed to be 50 and 30 nm, for the EBM and PBM, respectively, yielding volume fractions of 0.0081 and 0.0015 cm3/cm3 tissue. The remaining volume of the interstitial space is the ECM volume (34.04%).

Each region of the interstitial space can be represented as a porous medium that contains a solid fraction composed primarily of collagen that is unavailable to VEGF, and a fluid fraction that is accessible to VEGF. The size of the pores further limits the volume available for VEGF to diffuse. Therefore, the available volume in the ECM and basement membranes is calculated as the product of the volume, fluid fraction, and partition coefficient. The fluid fraction is the non-collagen fraction and is calculated by using the total collagen content in interstitial space. Given limited data for this measurement, we used 5%, the same value as in our previous models (24, 25, 87). The ratio of basement membrane collagen to total body collagen is assumed to be 0.3, which yields 0.0482 for the ratio of ECM collagen to total body collagen. The fluid fractions are then 0.7 for the basement membranes and 0.9318 for the ECM. The partition coefficient is the ratio of available fluid volume to interstitial fluid volume. We take 0.9 for the partition coefficient for the EBM (88), and the same value is used for the ECM and PBM, as it is difficult to distinguish basement membranes and the ECM (89). The available fluid volume for the ECM, EBM, and PBM are therefore 0.2916, 9.720 × 10−4, and 5.082 × 10−3 cm3/cm3 tissue, respectively.


Receptor densities and ECM binding site densities are listed in Table TableA2A2 in Appendix. VEGFR1, VEGFR2, and NRP1 on the luminal and abluminal surfaces of diseased EC surfaces and on tumor cells are based on quantitative flow cytometry measurements in ECs isolated from tumor tissue, as described in (25). We assume NRP2 surface concentration on tumor cells at the same level as NRP1.


To our knowledge, there are no data for the kinetics of mVEGF isoforms binding to glycosaminoglycan (GAG) chains or mouse receptors or cross-reactions between human and mouse isoforms and receptors. Therefore, we assume the kinetic rates for VEGF binding to and dissociation from receptors, co-receptors, and GAG chains in the ECM and basement membranes are the same as in our previous papers, based on experimental data (23,25, 87) and are given in Table TableA3A3 in Appendix. We use experimental data from Papadopoulos (11) for the on and off rates of VEGF binding to VEGF Trap.


Transport parameters for VEGF, anti-VEGF, and the VEGF/anti-VEGF complex are listed in Table TableA4A4 in Appendix. Parameters that govern transport between the normal and blood compartments are the same as in our previous model (23). Here, we explain specific transport parameters required for the addition of soluble factors sVEGFR1 and α2M and the tumor compartment. As in the previous model, myocytes are a source of VEGF and secrete the VEGF isoforms VEGF120 and VEGF164 at a ratio of 8:92 (90, 91). Additionally, tumor cells secrete VEGF into the tumor interstitium at a ratio of 50:50 for VEGF121:VEGF165, based on experimental quantification of mRNA isoform expression levels (92,96). Here, we also consider VEGF secretion by EC. We set the secretion ratio of VEGF120:VEGF164 by EC to be 10:90, similar to the isoform ratio in muscle tissue, since to our knowledge, this ratio has not been determined experimentally. Additionally, we assume normal and tumor EC secrete the same amount of VEGF; tumor EC are a small fraction of the total EC in the body, thus this assumption should not affect VEGF distribution. The rates of VEGF secretion by muscle fibers, EC, and tumor cells are determined by parameter optimization, fitting to experimental data from Rudge and coworkers (12).

This expanded model includes soluble factors sVEGFR1 and α2M. ECs are a source of sVEGFR1, and the rates of secretion by normal EC was set to 6 × 10−3 molecules/cell/s. Similar to VEGF secretion, we assume that sVEGFR1 secretion rate is the same for tumor EC. At steady state, the model estimated the distribution of sVEGFR1 in the body to be 0.4, 2.1, and 0.04 pM in the normal, blood, and tumor compartments, respectively. The level of sVEGFR1 in the plasma is within the range of experimental measurements, which range from 1 to 10 pM (97, 98). The clearance of α2M was set at 2.62 × 10−3 min−1, based on experimental measurements of the half-life, t1/2 (99), using ln(2)/t1/2. The synthesis of α2M was then estimated from mass balance at steady state, where the concentrations of native and active α2M are 1.4 μM (62) and 14 nM, respectively. We assume that the concentration of active α2M is 100-fold lower than that of the native form, based on experimental data for humans (100,102).

Molecular species are removed from the system via two mechanisms: plasma clearance and proteolytic degradation. The values of these parameters are in Table TableA4A4 in Appendix. For the normal endothelium, the permeability to sVEGFR1 and VEGF/sVEGFR1 is calculated using an empirical relation between the Stokes–Einstein radius, aE, and molecular weight [aE = 0.483 × (MW)0.386], the corresponding theoretical macromolecular permeability-surface area product, PS (103), and the capillary surface area, S. Taking microvascular permeability as PS/S, and the calculated value is on the order of 10−8 cm/s, between the normal and blood compartments. Since tumor vasculature is more permeable than normal microvessels (104), we assume that the microvascular permeability between the tumor and blood is an order of magnitude higher than permeability between normal and blood for both VEGF and the anti-VEGF or complex. Therefore, the permeability to VEGF is 4 × 10−7 and 3 × 10−7 cm/s for the anti-VEGF and VEGF/anti-VEGF complex. The permeability to sVEGFR1 and VEGF bound to sVEGFR1 is 1.5 × 10−7 cm/s.

Parameter estimation

The estimation of the VEGF secretion by muscle fibers, ECs, and tumor cells was achieved using the “lsqnonlin” function in MATLAB, as previously described (23). This algorithm solves the non-linear least squares problem using the trust-region-reflective optimization algorithm (105, 106), minimizing the weighted sum of the squared residuals (WSSR):


where Cexperimental, i is the ith experimentally measured plasma concentration data point, Csimulation, i(θ) is the ith simulated plasma concentration at the corresponding time point, Wi is the weight taken to be 1/Cexperimental, i, and n is the total number of experimental measurements. The minimization is subject to the upper and lower bounds of the free parameters, θ.

The two-compartment model was used to determine the rate of VEGF secretion by muscle fibers and ECs (“normal” and “EC” secretion, respectively), clearance of free and bound VEGF Trap, dissociation constant of VEGF and VEGF Trap. These five free parameters were fit to experimental data for the concentration profiles of VEGF/VEGF Trap complex and unbound VEGF Trap in mice at different doses of VEGF Trap (12), with a total of 58 data points. The initial value of the secretion rates was generated within the lower and upper bounds of 1.5 × 10−6 and 2 molecules/cell/s, respectively. The lower bound corresponds to 10 pg/ml and was set based on the limit of detection of standard ELISA kits used to measure (63). The half-life of VEGF Trap in mouse serum has been reported as 72 h (107), which corresponds to a clearance rate of 1.6 × 10−4 min−1, assuming clearance rate is equal to ln(2)/half-life. The upper and lower bounds of the clearance rates were one order of magnitude above and below this value, respectively. The upper and lower bounds for the dissociation constant were set to 0.25 and 5 pM, based on experimental data (11, 12). The baseline value of permeability of the normal tissue to VEGF Trap is 3 × 10−8 cm/s, as described above, and the bounds were one order of magnitude above and below this value. The optimal parameter values are reported as the mean and standard deviation of the 20 runs.

We used the three-compartment model to determine the rate at which VEGF is secreted by tumor cells (“tumor secretion”) and permeability of diseased tissue to free and complexed VEGF Trap. Tumor secretion was optimized to fit experimental data for the systemic VEGF Trap levels (free and complexed) reported by Rudge et al. (12). Experimental data for two human tumor xenografts (A673 rhabdomyosarcoma and HT1080 fibrosarcoma) were used separately; the total number of data points was 11 for A673 tumors and 10 for HT1080 tumors. Twenty runs were performed for each tumor, which either followed the average (baseline) or fast growth profile. This yields two conditions for each tumor type. The optimal secretion rates are reported as the mean and standard deviation of the 20 runs and should be interpreted as a range of values, where the values are dependent on the tumor microenvironment, tumor type, and growth profile.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Supplementary Material

The Supplementary Material for this article can be found online at


The authors thank Phillip Yen, members of the Popel Lab and Dr. Feilim Mac Gabhann for helpful discussions. This work was supported by NIH grant R01 CA138264 (Aleksander S. Popel), NIH fellowship F32 CA154213 (Stacey D. Finley), and UNCF/Merck Postdoctoral Fellowship (Stacey D. Finley).


Table A1

Geometric parameters.

Tumor cell external diameter12μmParan et al. (78)
Volume of one cell905μm3Calculated (see manuscript)
Surface area of one cell497μm2Calculated (see manuscript)
Average luminal diameter13.9μmSchaefer et al. (79)
Endothelial cell thickness0.5μmBased on normal microvessels (108)
Average external diameter14.9μmCalculated (see manuscript)
Cross-sectional area of one vessel175.3μm2Calculated (see manuscript)
Perimeter of one vessel57.7μmCalculated (see manuscript)
Capillary density655Capillaries/mm2Calculated (see manuscript)
Interstitial space35.0%cm2/cm3 tissueBased on (78, 83)
Cancer cells53.5%cm2/cm3 tissueCalculated (see manuscript)
Microvessels of which intravascular space11.5%cm2/cm3 tissueCalculated (see manuscript)
10.0%cm2/cm3 tissueBased on (84,86)
Tumor cells2939cm2/cm3 tissueCalculated (see manuscript)
Microvessels378cm2/cm3 tissueCalculated (see manuscript)
Thickness of tumor cell BM30nmBased on (109)
Basement membrane volume (tumor cells) of which available to VEGF0.00807cm3/cm3Calculated (see manuscript)
0.00508cm3/cm3 tissueCalculated (see manuscript)
Thickness of microvessel BM50nmBased on (109)
Basement membrane volume (microvessels) of which available to VEGF0.00154cm3/cm3 tissueCalculated (see manuscript)
0.000972cm3/cm3 tissueCalculated (see manuscript)
Extracellular matrix volume of which available to VEGF0.3375cm3/cm3 tissueCalculated (see manuscript)
0.2892cm3/cm3 tissueCalculated (see manuscript)

Table A2

Concentrations in tumor compartment.

Luminal EC3750Dimers/EC
Abluminal EC3750Dimers/EC
Luminal EC300Dimers/EC
Abluminal EC300Dimers/EC
Luminal EC39,748Dimers/EC
Abluminal EC39,748Dimers/EC
ECM binding density0.75μM
EBM binding density13μM
PBM binding density13μM

EC, endothelial cell; TC, tumor cell.

Table A3

Kinetic parameters.

kon3 × 107M−1 s−1Mac Gabhann and Popel (87), Stefanini et al. (24)
koff10−3s−1Mac Gabhann and Popel (87), Stefanini et al. (24)
Kd33pMMac Gabhann and Popel (87), Stefanini et al. (24)
kon107M−1 s−1Mac Gabhann and Popel (87), Stefanini et al. (24)
koff10−3s−1Mac Gabhann and Popel (87), Stefanini et al. (24)
Kd100pMMac Gabhann and Popel (87), Stefanini et al. (24)
kon3.2 × 106M−1 s−1Mac Gabhann and Popel (87), Stefanini et al. (24)
koff10−3s−1Mac Gabhann and Popel (87), Stefanini et al. (24)
Kd312.5pMMac Gabhann and Popel (87), Stefanini et al. (24)
kon4.20 × 105M−1 s−1Mac Gabhann and Popel (87), Stefanini et al. (24)
koff10−2s−1Mac Gabhann and Popel (87), Stefanini et al. (24)
Kd24pMMac Gabhann and Popel (87), Stefanini et al. (24)
kc1014(mol/cm2)−1 s−1Mac Gabhann and Popel (87), Stefanini et al. (24)
koff10−2s−1Mac Gabhann and Popel (87), Stefanini et al. (24)
kcV165R2, N13.1 × 1013(mol/cm2)−1 s−1Mac Gabhann and Popel (87), Stefanini et al. (24)
koffV165R2, N110−3s−1Mac Gabhann and Popel (87), Stefanini et al. (24)
kcV165N1, R21014(mol/cm2)−1 s−1Mac Gabhann and Popel (87), Stefanini et al. (24)
koffV165N1, R210−3s−1Mac Gabhann and Popel (87), Stefanini et al. (24)
kint2.8 × 10−4s−1Mac Gabhann and Popel (87), Stefanini et al. (24)
kon3.75 × 108M−1 s−1Calculated
koff1.35 × 10−5s−1Papadopoulos et al. (11)
Kd0.36pMPapadopoulos et al. (11)
kon4.10 × 107M−1 s−1Calculated
koff2.01 × 10−5s−1Papadopoulos et al. (11)
Kd0.49pMPapadopoulos et al. (11)
kon2.15 × 107M−1 s−1Calculated
koff1.23 × 10−5s−1Papadopoulos et al. (11)
Kd0.572pMPapadopoulos et al. (11)
kon2.80 × 107M−1 s−1Calculated
koff1.64 × 10−5s−1Papadopoulos et al. (11)
Kd0.586pMPapadopoulos et al. (11)
kon25M−1 s−1Calculated
Kd4.0μMBhattacharjee et al. (110)
kon2.4 × 102M−1 s−1Calculated
Kd0.42μMBhattacharjee et al. (110)
kon3 × 107M−1 s−1Assumed, based on VEGF binding to VEGFR1
kon5.6 × 106M−1 s−1Calculated
koff10−2s−1Assumed, based on VEGFR1 coupling to NRP1
Kd1.8nMFuh et al. (111)
kon4.20 × 105M−1 s−1Assumed, based on VEGF165 binding to GAG

Table A4

Transport parameters.

VEGF4.0 × 10−8cm/sStefanini et al. (24)
Anti-VEGF and VEGF/anti-VEGF complex3.0 × 10−8cm/sStefanini et al. (24)
Soluble VEGFR11.5 × 10−8cm/sCalculated, see text
Soluble VEGFR1/VEGF complex1.5 × 10−8cm/sCalculated, see text
VEGF4.0 × 10−7cm/sAssumed, see text
Anti-VEGF and VEGF/anti-VEGF complex3.0 × 10−7cm/sAssumed, see text
Soluble VEGFR11.5 × 10−7cm/sAssumed, see text
Soluble VEGFR1/VEGF complex1.5 × 10−7cm/sAssumed, see text
VEGF2.3 × 10−1min−1Folkman (112)
Anti-VEGF8.9 × 10−4min−1Yen et al. (23)
VEGF/anti-VEGF complex2.8 × 10−4min−1Yen et al. (23)
Soluble VEGFR13.0 × 10−4min−1Wu et al. (113)
Soluble VEGFR1/VEGF complex3.0 × 10−4min−1Wu et al. (113)
Alpha-2-macroglobulin (α2M)2.6 × 10−3min−1Hudson et al. (99)
α2M/VEGF complex2.6 × 10−3min−1Assumed, based on α2M
α2M/VEGF/anti-VEGF complex2.6 × 10−3min−1Assumed, based on α2M
Activated alpha-2-macroglobulin (α2Mfast)2.4 × 10−1min−1Imber and Pizzo (114)
α2M/VEGF complex2.6 × 10−3min−1Assumed, based on α2Mfast
Soluble VEGFR11.2 × 10−2min−1Assumed based on VEGF
Soluble VEGFR1/VEGF complex1.2 × 10−2min−1Assumed based on VEGF
Alpha-2-macroglobulin1.8 × 1010Molecules/cm3 tissue/sCalculated, see text
Activated alpha-2-macroglobulin1.6 × 1010Molecules/cm3 tissue/sCalculated, see text

Figure A1

An external file that holds a picture, illustration, etc.
Object name is fonc-03-00196-a001.jpg

Predicted systemic VEGF Trap levels for fast-growing tumors. The model predicts the plasma levels of free VEGF Trap (black lines), mouse VEGF bound to VEGF Trap (blue lines), and human VEGF bound to VEGF Trap (red lines) for fast-growing tumors. VEGF Trap was administered twice per week for 2 weeks at doses of 0.5, 1, 2.5, 10, and 25 mg/kg. The simulated results are shown for the optimized model where the secretion rates of VEGF by myocytes, EC, and tumor cells were fit to experimental data (circles). We use the mean (solid lines) and 1 SD (dashed lines) of the fitted secretion rates. (A) A673 tumor; and (B) HT1080 tumor.

Figure A2

An external file that holds a picture, illustration, etc.
Object name is fonc-03-00196-a002.jpg

Optimized VEGF secretion rates. The model parameters were optimized to fit experimental data, and the values of normal, EC, and tumor VEGF secretion rates were determined. The mean optimal secretion rates and standard deviation of 20 optimization runs for fast-growing tumors are shown.


1. Rennel ES, Harper SJ, Bates DO. Therapeutic potential of manipulating VEGF splice isoforms in oncology. Future Oncol (2009) 5:703–1210.2217/fon.09.33 [PMC free article] [PubMed] [Cross Ref]
2. Dokun AO, Annex BH. The VEGF165b “ICE-o-form” puts a chill on the VEGF story. Circ Res (2011) 109:246–710.1161/CIRCRESAHA.111.249953 [PMC free article] [PubMed] [Cross Ref]
3. Koch S, Tugues S, Li X, Gualandi L, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochem J (2011) 437:169–8310.1042/BJ20110301 [PubMed] [Cross Ref]
4. Olsson A-K, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling – in control of vascular function. Nat Rev Mol Cell Biol (2006) 7:359–7110.1038/nrm1911 [PubMed] [Cross Ref]
5. Cao Y. Therapeutic angiogenesis for ischemic disorders: what is missing for clinical benefits? Discov Med (2010) 9:179–84 [PubMed]
6. Roy RS, Roy B, Sengupta S. Emerging technologies for enabling proangiogenic therapy. Nanotechnology (2011) 22:494004.10.1088/0957-4484/22/49/494004 [PubMed] [Cross Ref]
7. Al-Latayfeh M, Silva PS, Aiello LP. Antiangiogenic therapy for ischemic retinopathies. Cold Spring Harb Perspect Med (2012) 2:a006411.10.1101/cshperspect.a006411 [PMC free article] [PubMed] [Cross Ref]
8. Jayson GC, Hicklin DJ, Ellis LM. Antiangiogenic therapy – evolving view based on clinical trial results. Nat Rev Clin Oncol (2012) 9:297–30310.1038/nrclinonc.2012.8 [PubMed] [Cross Ref]
9. Genentech, Inc Avastin Prescribing Information. (2011) [accessed September 2011]. Available from:
10. Gaya A, Tse V. A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treat Rev (2012) 38:484–9310.1016/j.ctrv.2011.12.008 [PubMed] [Cross Ref]
11. Papadopoulos N, Martin JD, Ruan Q, Rafique A, Rosconi MP, Shi E, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis (2012) 15:171–8510.1007/s10456-011-9249-6 [PMC free article] [PubMed] [Cross Ref]
12. Rudge JS, Holash J, Hylton D, Russell M, Jiang S, Leidich R, et al. VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci U S A (2007) 104:18363–7010.1073/pnas.0708865104 [PubMed] [Cross Ref]
13. Singh M, Ferrara N. Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. Nat Biotechnol (2012) 30:648–5710.1038/nbt.2286 [PubMed] [Cross Ref]
14. Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol (2013) 31:2205–1810.1200/JCO.2012.46.3653 [PMC free article] [PubMed] [Cross Ref]
15. Peirce SM. Computational and mathematical modeling of angiogenesis. Microcirculation (2008) 15:739–5110.1080/10739680802220331 [PMC free article] [PubMed] [Cross Ref]
16. Qutub AA, Mac Gabhann F, Karagiannis ED, Vempati P, Popel AS. Multiscale models of angiogenesis. IEEE Eng Med Biol Mag (2009) 28:14–3110.1109/MEMB.2009.931791 [PMC free article] [PubMed] [Cross Ref]
17. Stefanini MO, Qutub AA, Mac Gabhann F, Popel AS. Computational models of VEGF-associated angiogenic processes in cancer. Math Med Biol (2012) 29:85–9410.1093/imammb/dqq025 [PubMed] [Cross Ref]
18. Byrne HM. Dissecting cancer through mathematics: from the cell to the animal model. Nat Rev Cancer (2010) 10:221–3010.1038/nrc2808 [PubMed] [Cross Ref]
19. Young RJ, Reed MWR. Anti-angiogenic therapy: concept to clinic. Microcirculation (2012) 19:115–2510.1111/j.1549-8719.2011.00147.x [PubMed] [Cross Ref]
20. Duda DG, Munn LL, Jain RK. Can we identify predictive biomarkers for antiangiogenic therapy of cancer using mathematical models? J Natl Cancer Inst (2013) 105:762–510.1093/jnci/djt114 [PMC free article] [PubMed] [Cross Ref]
21. Wehland M, Bauer J, Magnussion NE, Infanger M, Grimm D. Biomarkers for anti-angiogenic therapy in cancer. Int J Mol Sci (2013) 14:9338–6410.3390/ijms14059338 [PMC free article] [PubMed] [Cross Ref]
22. Finley SD, Popel AS. Effect of tumor microenvironment on tumor VEGF during anti-VEGF treatment: systems biology predictions. J Natl Cancer Inst (2013) 105:802–1110.1093/jnci/djt093 [PMC free article] [PubMed] [Cross Ref]
23. Yen P, Finley SD, Engel-Stefanini MO, Popel AS. A two-compartment model of VEGF distribution in the mouse. PLoS ONE (2011) 6:e27514.10.1371/journal.pone.0027514 [PMC free article] [PubMed] [Cross Ref]
24. Stefanini MO, Wu FTH, Mac Gabhann F, Popel AS. A compartment model of VEGF distribution in blood, healthy and diseased tissues. BMC Syst Biol (2008) 2:77.10.1186/1752-0509-2-77 [PMC free article] [PubMed] [Cross Ref]
25. Finley SD, Engel-Stefanini MO, Imoukhuede PI, Popel AS. Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies. BMC Syst Biol (2011) 5:193.10.1186/1752-0509-5-193 [PMC free article] [PubMed] [Cross Ref]
26. Finley SD, Popel AS. Predicting the effects of anti-angiogenic agents targeting specific VEGF isoforms. AAPS J (2012) 14:500–910.1208/s12248-012-9363-4 [PMC free article] [PubMed] [Cross Ref]
27. Chauhan VP, Stylianopoulos T, Martin JD, Popovic Z, Chen O, Kamoun WS, et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol (2012) 7:383–810.1038/nnano.2012.45 [PMC free article] [PubMed] [Cross Ref]
28. Gavin TP, Ruster RS, Carrithers JA, Zwetsloot KA, Kraus RM, Evans CA, et al. No difference in the skeletal muscle angiogenic response to aerobic exercise training between young and aged men. J Physiol (2007) 585:231–910.1113/jphysiol.2007.143198 [PubMed] [Cross Ref]
29. Hellsten Y, Rufener N, Nielsen JJ, Hoier B, Krustrup P, Bangsbo J. Passive leg movement enhances interstitial VEGF protein, endothelial cell proliferation, and eNOS mRNA content in human skeletal muscle. Am J Physiol Regul Integr Comp Physiol (2008) 294:R975–8210.1152/ajpregu.00677.2007 [PubMed] [Cross Ref]
30. Hansen-Algenstaedt N, Nielsen JJ, Saltin B, Hellsten Y. Exercise training normalizes skeletal muscle vascular endothelial growth factor levels in patients with essential hypertension. J Hypertens (2010) 28:1176–8510.1097/HJH.0b013e3283379120 [PubMed] [Cross Ref]
31. Hoier B, Rufener N, Bojsen-Moller J, Bangsbo J, Hellsten Y. The effect of passive movement training on angiogenic factors and capillary growth in human skeletal muscle. J Physiol (2010) 588:3833–4510.1113/jphysiol.2010.190439 [PubMed] [Cross Ref]
32. Hoier B, Nordsborg N, Andersen S, Jensen L, Nybo L, Bangsbo J, et al. Pro- and anti-angiogenic factors in human skeletal muscle in response to acute exercise and training. J Physiol (2012) 590:595–60610.1113/jphysiol.2011.216135 [PubMed] [Cross Ref]
33. Hoier B, Passos M, Bangsbo J, Hellsten Y. Intense intermittent exercise provides weak stimulus for VEGF secretion and capillary growth in skeletal muscle. Exp Physiol (2013) 98:585–9710.1113/expphysiol.2012.067967 [PubMed] [Cross Ref]
34. Le X-F, Mao W, Lu C, Thornton A, Heymach JV, Sood AK, et al. Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2. Cell Cycle (2008) 7:3747–5810.4161/cc.7.23.7212 [PMC free article] [PubMed] [Cross Ref]
35. Bjorndahl M, Cao R, Eriksson A, Cao Y. Blockage of VEGF-induced angiogenesis by preventing VEGF secretion. Circ Res (2004) 94:1443–5010.1161/ [PubMed] [Cross Ref]
36. Kavitha CV, Agarwal C, Argawal R, Deep G. Asiatic acid inhibits pro-angiogenic effects of VEGF and human gliomas in endothelial cell culture models. PLoS ONE (2011) 6:e22745.10.1371/journal.pone.0022745 [PMC free article] [PubMed] [Cross Ref]
37. van der Bilt ARM, van Scheltinga AGTT, Timmer-Bosscha H, Schroder CP, Pot L, Kosterink JGW, et al. Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model. Clin Cancer Res (2012) 18:6306–1410.1158/1078-0432.CCR-12-0406 [PubMed] [Cross Ref]
38. Leith JT, Michelson S. Secretion rates and levels of vascular endothelial growth factor in clone A or HCT-8 human colon tumour cells as a function of oxygen concentration. Cell Prolif (1995) 28:415–3010.1111/j.1365-2184.1995.tb00082.x [PubMed] [Cross Ref]
39. Rofstad EK, Halsor EF. Vascular endothelial growth factor, interleukin 9, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Res (2000) 60:4932–8 [PubMed]
40. Pilch H, Schlenger K, Steiner E, Brockerhoff P, Knapstein P, Vaupel P. Hypoxia-stimulated expression of angiogenic growth factors in cervical cancer cells and cervical cancer-derived fibroblasts. Int J Gynecol Cancer (2001) 11:137–4210.1046/j.1525-1438.2001.011002137.x [PubMed] [Cross Ref]
41. Salnikov AV, Heldin N-E, Stuhr LB, Wiig H, Gerber H-P, Reed RK, et al. Inhibition of carcinoma cell-derived VEGF reduces inflammatory characteristics in xenograft carcinoma. Int J Cancer (2006) 119:2795–80210.1002/ijc.22217 [PubMed] [Cross Ref]
42. Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem (2003) 278:12605–810.1074/jbc.C300012200 [PubMed] [Cross Ref]
43. Bocci G, Man S, Green SK, Francia G, Ebos JM, du Manoir JM, et al. Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer Res (2004) 64:6616–2510.1158/0008-5472.CAN-04-0401 [PubMed] [Cross Ref]
44. Keyes KA, Mann L, Cox K, Treadway P, Iversen P, Chen Y-F, et al. Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology. Cancer Chemother Pharmacol (2003) 51:321–7 [PubMed]
45. Rullman E, Rundqvist H, Wagsater D, Fischer H, Eriksson P, Sundberg CJ, et al. A single bout of exercise activates matrix metalloproteinase in human skeletal muscle. J Appl Physiol (2007) 102:2346–5110.1152/japplphysiol.00822.2006 [PubMed] [Cross Ref]
46. Kut C, Mac Gabhann F, Popel AS. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer (2007) 97:978–8510.1038/sj.bjc.6603923 [PMC free article] [PubMed] [Cross Ref]
47. Bernaards C, Hegde P, Chen D, Holmgren E, Zheng M, Jubb AM, et al. Circulating vascular endothelial growth factor (VEGF) as a biomarker for bevacizumab-based therapy in metastatic colorectal, non-small cell lung, and renal cell cancers: analysis of phase III studies. J Clin Oncol (2010) 28:10519
48. Sanmartin E, Jantus E, Blasco A, Sirera R, Caballero C, Gallach S, et al. Plasma levels of VEGF-A and VEGFR-2 in advanced NSCLC. J Clin Oncol (2010) 28:10623
49. Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol (2009) 27:3020–610.1200/JCO.2008.21.1771 [PMC free article] [PubMed] [Cross Ref]
50. Hoff BA, Bhojani MS, Rudge J, Chenevert TL, Meyer CR, Galban S, et al. DCE and DW-MRI monitoring of vascular disruption following VEGF-Trap treatment of a rat glioma model. NMR Biomed (2011) 25:935–4210.1002/nbm.1814 [PubMed] [Cross Ref]
51. Zhang Q-X, Magover CJ, Mack CA, Budenbender KT, Ko W, Rosengart T. Vascular endothelial growth factor is the major angiogenic factor in omentum: mechanism of the omentum-mediated angiogenesis. J Surg Res (1997) 67:147–5410.1006/jsre.1996.4983 [PubMed] [Cross Ref]
52. Yuan A, Lin C-Y, Chou C-H, Shih C-M, Chen C-Y, Cheng H-W, et al. Functional and structural characteristics of tumor angiogenesis in lung cancers overexpressing different VEGF isoforms assessed by DCE- and SSCE-MRI. PLoS ONE (2011) 6:e16062.10.1371/journal.pone.0016062 [PMC free article] [PubMed] [Cross Ref]
53. Woolard J, Wang W-Y, Bevan HS, Qiu Y, Morbidelli L, Pritchard-Jones RO, et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res (2004) 64:7822–3510.1158/0008-5472.CAN-04-0934 [PubMed] [Cross Ref]
54. Bates DO, Catalano PJ, Symonds KE, Varey AHR, Ramani P, O’Dwyer PJ, et al. Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab. Clin Cancer Res (2012) 18:6384–9110.1158/1078-0432.CCR-12-2223 [PMC free article] [PubMed] [Cross Ref]
55. Achen MG, Stacker SA. Vascular endothelial growth factor-D: signaling mechanisms, biology, and clinical relevance. Growth Factors (2012) 30:283–9610.3109/08977194.2012.704917 [PubMed] [Cross Ref]
56. Benedito R, Rocha SF, Woeste M, Zamykal M, Radtke F, Casanovas O, et al. Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling. Nature (2012) 484:110–410.1038/nature10908 [PubMed] [Cross Ref]
57. Chen JC, Chang YW, Hong CC, Yu YH, Su JL. The role of the VEGF-C/VEGFRs axis in tumor progression and therapy. Int J Mol Med (2012) 14:88–10710.3390/ijms14010088 [PMC free article] [PubMed] [Cross Ref]
58. Battinelli EM, Markens BA, Italiano JE., Jr. Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. Blood (2011) 118:1359–6910.1182/blood-2011-02-334524 [PubMed] [Cross Ref]
59. Yankeelov TE, Lepage M, Chakravarthy A, Broome EE, Niermann KJ, Kelley MC, et al. Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer. Magn Reson Imaging (2007) 25:1–1310.1016/j.mri.2006.09.006 [PMC free article] [PubMed] [Cross Ref]
60. Mitchell EP. Targeted therapy for metastatic colorectal cancer: role of aflibercept. Clin Colorectal Cancer (2012) 12(2):73–8510.1016/j.clcc.2012.08.001 [PubMed] [Cross Ref]
61. Barrett AJ, Starkey PM. The interaction of alpha 2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism. Biochem J (1973) 133:709–24 [PubMed]
62. Webb DJ, Wen J, Lysiak JJ, Umans L, Van Leuven F, Gonias SL. Murine a-macroglobulins demonstrate divergent activities as neutralizers of transforming growth factor-b and as inducers of nitric oxide synthesis. J Biol Chem (1996) 271:24982–810.1074/jbc.271.40.24982 [PubMed] [Cross Ref]
63. Jelkmann W. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem (2001) 47:617–23 [PubMed]
64. Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell (2007) 130:691–70310.1016/j.cell.2007.06.054 [PMC free article] [PubMed] [Cross Ref]
65. dela Paz NG, Walshe TE, Leach L, Saint-Geniez M, D’Amore PA. Role of shear-stress-induced VEGF expression in endothelial cell survival. J Cell Sci (2012) 125:831–4310.1242/jcs.084301 [PubMed] [Cross Ref]
66. Van den Berg CL, Cox GN, Stroh CA, Hilsenbeck SG, Weng C-N, McDermott MJ, et al. Polyethylene glycol conjugated insulin-like growth factor binding protein 1 (IGFBP-1) inhibits growth of breast cancer in athymic mice. Eur J Cancer (1997) 33:1108–1310.1016/S0959-8049(97)00071-3 [PubMed] [Cross Ref]
67. Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Yla-Herttuala S, Jaattela M, et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res (2001) 61:1786–90 [PubMed]
68. Cameron IL, Sun L-Z, Short N, Hardman WE, Williams CD. Therapeutic Electromagnetic Field (TEMF) and gamma irradiation on human breast cancer xenograft growth, angiogenesis and metastasis. Cancer Cell Int (2005) 5:23.10.1186/1475-2867-5-17 [PMC free article] [PubMed] [Cross Ref]
69. Divisova J, Kuiatse I, Lazard Z, Weiss H, Vreeland F, Hadsell DL, et al. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat (2006) 98(3):315–2710.1007/s10549-006-9168-1 [PubMed] [Cross Ref]
70. Wu Y, Hooper AT, Zhong Z, Witte L, Bohlen P, Rafii S, et al. The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma. Int J Cancer (2006) 119:1519–2910.1002/ijc.21865 [PubMed] [Cross Ref]
71. Groth-Pedersen L, Ostenfeld MS, Hoyer-Hansen M, Nylandsted J, Jaattela M. Vincristine induces dramatic lysosomal changes and sensitizes cancer cells to lysosome-destabilizing siramesine. Cancer Res (2007) 67:2217–2510.1158/0008-5472.CAN-06-3520 [PubMed] [Cross Ref]
72. Rajhans R, Nair S, Holden AH, Kumar R, Takmel RR, Vadlamudi RK. Oncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucine-rich protein 1/modulator of the nongenomic actions of the estrogen receptor. Cancer Res (2007) 67:5505–1210.1158/0008-5472.CAN-06-3647 [PMC free article] [PubMed] [Cross Ref]
73. Gully CP, Zhang F, Chen J, Yeung JA, Valazquez-Torres G, Wang E, et al. Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer. Mol Cancer (2010) 9:42.10.1186/1476-4598-9-42 [PMC free article] [PubMed] [Cross Ref]
74. Koskimaki JE, Rosca EV, Rivera CG, Lee E, Chen W, Pandey NB, et al. Serpin-derived peptides are antiangiogenic and suppress breast tumor xenograft growth. Trxansl Oncol (2012) 5:92–7 [PMC free article] [PubMed]
75. Saltelli A, Bolado R. An alternative way to compute Fourier amplitude sensitivity test (FAST). Comput Stat Data Anal (2008) 26:445–6010.1016/S0167-9473(97)00043-1 [Cross Ref]
76. Marino S, Hogue IB, Ray CJ, Kirschner DE. A methodology for performing global uncertainty and sensitivity analysis in systems biology. J Theor Biol (2008) 254:178–9610.1016/j.jtbi.2008.04.011 [PMC free article] [PubMed] [Cross Ref]
77. Tan WH, Popel AS, Mac Gabhann F. Computational model of Gab1/2-dependent VEGFR2 pathway to Akt activation. PLoS ONE (2013) 8:e67438.10.1371/journal.pone.0067438 [PMC free article] [PubMed] [Cross Ref]
78. Paran Y, Bendel P, Margalit R, Degani H. Water diffusion in the different microenvironments of breast cancer. NMR Biomed (2004) 17:170–8010.1002/nbm.882 [PubMed] [Cross Ref]
79. Schaefer C, Schroeder M, Fuhrhop I, Viezens L, Otten J, Fiedler W, et al. Primary tumor dependent inhibition of tumor growth, angiogenesis, and perfusion of secondary breast cancer in bone. J Orth Res (2011) 29:1251–810.1002/jor.21402 [PubMed] [Cross Ref]
80. Kim E, Stamatelos SK, Cebulla J, Bhujwalla ZM, Popel AS, Pathak AP. Multiscale imaging and computational modeling of blood flow in the tumor vasculature. Ann Biomed Eng (2012) 40:2425–4110.1007/s10439-012-0585-5 [PubMed] [Cross Ref]
81. Olewniczak S, Chosia M, Kwas A, Kram A, Domagala W. Angiogenesis and some prognostic parameters of invasive ductal breast carcinoma in women. Pol J Pathol (2002) 53:183–8 [PubMed]
82. Olewniczak S, Chosia M, Kolodziej B, Kwas A, Kram A, Domagala W. Angiogenesis as determined by computerised image analysis and the risk of early relapse in women with invasive ductal breast carcinoma. Pol J Pathol (2003) 54:53–9 [PubMed]
83. Hassid Y, Furman-Haran E, Margalit R, Eilam R, Degani H. Noninvasive magnetic resonance imaging of transport and interstitial fluid pressure in ectopic human lung tumors. Cancer Res (2006) 66:4159–6610.1158/0008-5472.CAN-05-3289 [PubMed] [Cross Ref]
84. Lewin M, Bredow S, Sergeyev N, Marecos E, Bodganov A, Jr., Weissleder R. In vivo assessment of vascular endothelial growth factor-induced angiogenesis. Int J Cancer (1999) 83:798–80210.1002/(SICI)1097-0215(19991210)83:6<798:AID-IJC16>3.0.CO;2-W [PubMed] [Cross Ref]
85. Bogin L, Margalit R, Mispelter J, Degani H. Parametric imaging of tumor perfusion using flow- and permeability-limited tracers. J Magn Reson Imaging (2002) 16:289–9910.1002/jmri.10159 [PubMed] [Cross Ref]
86. Cao M, Liang Y, Shen C, Miller KD, Stantz KM. Developing DCE-CT to quantify intra-tumor heterogeneity in breast tumors with different angiogenic phenotype. IEEE Trans Med Imaging (2009) 28:861–7110.1109/TMI.2008.2012035 [PubMed] [Cross Ref]
87. Mac Gabhann F, Popel AS. Targeting neuropilin-1 to inhibit VEGF signaling in cancer: comparison of therapeutic approaches. PLoS Comp Biol (2006) 2:e180.10.1371/journal.pcbi.0020180 [PubMed] [Cross Ref]
88. Yuan F, Krol A, Tong S. Available space and extracellular transport of macromolecules: effects of pore size and connectedness. Ann Biomed Eng (2001) 29:1150–810.1114/1.1424915 [PubMed] [Cross Ref]
89. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol (2000) 156:1363–8010.1016/S0002-9440(10)65006-7 [PubMed] [Cross Ref]
90. Ng YS, Rohan R, Sunday ME, Demello DE, D’Amore PA. Differential expression of VEGF isoforms in mouse during development and in the adult. Dev Dyn (2001) 220:112–2110.1002/1097-0177(2000)9999:9999<::AID-DVDY1093>3.0.CO;2-D [PubMed] [Cross Ref]
91. Gustafsson T, Ameln H, Fischer H, Sundberg CJ, Timmons JA, Jansson E. VEGF-A splice variants and related receptor expression in human skeletal muscle following submaximal exercise. J Appl Physiol (2005) 98:2137–4610.1152/japplphysiol.01402.2004 [PubMed] [Cross Ref]
92. Cheung N, Wong MP, Yuen ST, Leung SY, Chung LP. Tissue-specific expression pattern of vascular endothelial growth factor isoforms in the malignant transformation of lung and colon. Hum Pathol (1998) 29:910–410.1016/S0046-8177(98)90195-2 [PubMed] [Cross Ref]
93. Yuan A, Yu CJ, Luh KT, Lin FY, Kuo SH, Yang PC. Quantification of VEGF mRNA expression in non-small cell lung cancer using a real-time quantitative reverse transcription-PCR assay and a comparison with quantitative competitive reverse transcription-PCR. Lab Invest (2000) 2000:11 [PubMed]
94. Stimpfl M, Tong D, Fasching B, Schuster E, Obermair A, Leodolter S, et al. Vascular endothelial growth factor splice variants and their prognostic value in breast and ovarian cancer. Clin Cancer Res (2002) 8:2253–9 [PubMed]
95. Ljungberg B, Jacobsen J, Haggstrom-Rudolfssson S, Rasmuson T, Lindh G, Grankvist K. Tumor vascular endothelial growth factor (VEGF) mRNA in relation to serum VEGF protein levels and tumour progression in human renal cell carcinoma. Urol Res (2003) 31:335–4010.1007/s00240-003-0346-x [PubMed] [Cross Ref]
96. Zygalaki E, Tsaroucha EG, Kaklamanis L, Lianidou ES. Quantitative real-time reverse transcription-PCR study of the expression of vascular endothelial growth factor (VEGF) splice variants and VEGF receptors (VEGFR-1 and VEGFR-2) in non-small cell lung cancer. Clin Chem (2007) 53:1433–910.1373/clinchem.2007.086819 [PubMed] [Cross Ref]
97. Roland CL, Dineen SP, Lynn KD, Sullivan LA, Dellinger MT, Sadegh L, et al. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol Cancer Ther (2009) 8:1761–7110.1158/1535-7163.MCT-09-0280 [PubMed] [Cross Ref]
98. Blankenberg FG, Levashova Z, Sarkar SK, Pizzonia J, Backer MV, Bacher JM. Noninvasive assessment of tumor VEGF receptors in response to treatment with pazopanib: a molecular imaging study. Transl Oncol (2010) 3:56–64 [PMC free article] [PubMed]
99. Hudson NW, Kehoe JM, Koo PH. Mouse alpha-macroglobulin. Structure, function, and a molecular model. Biochem J (1987) 248:837–45 [PubMed]
100. Banks RE, Evans SW, Van Leuven F, Alexander D, McMahon MJ, Whicher JT. Measurement of the “fast” or complexed form of α2-macroglobulin in biological fluids using a sandwich enzyme immunoassay. J Immunol Methods (1990) 126:13–2010.1016/0022-1759(90)90006-H [PubMed] [Cross Ref]
101. Zucker S, Lysik RM, Zarrabi MH, Fiore JJ, Strickland DK. Proteinase-alpha2 macroglobulin complexes are not increased in plasma of patients with cancer. Int J Cancer (1991) 48:399–40310.1002/ijc.2910480316 [PubMed] [Cross Ref]
102. Jespersen MH, Jensen J, Rasmussen LH, Ejlersen E, Moller-Petersen J, Sperling-Petersen HU. The reference range for complexed a2-macroglobulin human plasma: development of a new enzyme linked in immunosorbent assay (ELISA) for quantitation of complexed a2-macroglobulin. Scand J Clin Lab Invest (1993) 53:639–4810.1080/00365519309092565 [PubMed] [Cross Ref]
103. Garlick DG, Renkin EM. Transport of large molecules from plasma to interstitial fluid and lymph in dogs. Am J Physiol (1970) 219:1595–605 [PubMed]
104. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev (2011) 91:1071–12110.1152/physrev.00038.2010 [PMC free article] [PubMed] [Cross Ref]
105. Coleman TF, Li Y. On the convergence of reflective Newton methods for large-scale nonlinear minimization subject to bounds. Math Program (1994) 67:189–22410.1007/BF01582221 [Cross Ref]
106. Coleman TF, Li Y. An interior, trust region approach for nonlinear minimization subject to bounds. SIAM J Optim (1996) 6:418–4510.1137/0806023 [Cross Ref]
107. Wachsberger PR, Burd R, Cardi C, Thakur M, Daskalakis C, Holash J, et al. VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int J Radiat Oncol Biol Phys (2007) 67:1526–3710.1016/j.ijrobp.2006.11.011 [PubMed] [Cross Ref]
108. Hall JE. The circulation. In: Hall JE, editor. editor. Guyton and Hall Textbook of Medical Physiology. 12th ed. Philadelphia, PA: W.B. Saunders Company; (2011). p. 177–90
109. Baluk P, Morikawa S, Haskell A, Mancuso M, McDonald DM. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol (2003) 163:1801–1510.1016/S0002-9440(10)63540-7 [PubMed] [Cross Ref]
110. Bhattacharjee G, Asplin IR, Wu SM, Gawdi G, Pizzo SV. The conformation-dependent interaction of alpha-2-macroglobulin with vascular endothelial growth factor. J Biol Chem (2000) 275:26806–11 [PubMed]
111. Fuh G, Garcia KC, de Vos AM. The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1. J Biol Chem (2000) 275:26690–5 [PubMed]
112. Folkman J. Angiogenesis in cancer, vascular rheumatoid and other disease. Nat Med (1995) 1:27–3110.1038/nm0195-27 [PubMed] [Cross Ref]
113. Wu FTH, Stefanini MO, Mac Gabhann F, Popel AS. A compartment model of VEGF distribution in humans in the presence of soluble VEGF receptor-1 acting as a ligand trap. PLoS ONE (2009) 4:e5108.10.1371/journal.pone.0005108 [PMC free article] [PubMed] [Cross Ref]
114. Imber MJ, Pizzo SV. Clearance and binding of two electrophoretic “fast” forms of human alpha-2-macroglobulin. J Biol Chem (1981) 256:8134–9 [PubMed]

Articles from Frontiers in Oncology are provided here courtesy of Frontiers Media SA